rs16941 — BRCA1 E1038G

BRCA1 E1038G — A Common Variant, Not a Pathogenic Mutation

The BRCA1 gene is one of the most well-known genes in human genetics, encoding a large protein essential for homologous recombination DNA repair¹¹ homologous recombination DNA repair
A high-fidelity mechanism for repairing double-strand DNA breaks using the sister chromatid as a template; BRCA1 orchestrates the assembly of the repair complex. Pathogenic mutations in BRCA1 dramatically increase lifetime risks of breast (60-70%) and ovarian (40-50%) cancer. However, not every variant in BRCA1 is pathogenic. The E1038G variant (rs16941) is a common missense polymorphism carried by roughly one-third of the global population — fundamentally different from the rare, high-penetrance BRCA1 mutations that drive clinical management decisions like prophylactic surgery.

This distinction is critical. If you carry this variant, it does not mean you have a "BRCA1 mutation" in the clinical sense. The E1038G variant has been classified as likely benign to benign by most ClinVar submitters, though a small number of association studies have reported modest risk elevations (OR ~1.1-1.3) for breast cancer. Current evidence places it in the category of a common variant with uncertain-to-modest biological significance — potentially a minor risk modifier, but not an actionable pathogenic finding.

The Mechanism

The rs16941 variant causes a glutamic acid-to-glycine substitution at position 1038 of the BRCA1 protein. This residue sits in the region between the coiled-coil domain and the BRCT repeats²² BRCT repeats
BRCA1 C-terminal domains that recognize phosphorylated proteins at DNA damage sites; critical for recruiting repair factors to double-strand breaks. The change replaces a large, negatively charged amino acid (glutamic acid) with the smallest amino acid (glycine), potentially altering local protein flexibility and interactions.

Functional studies³³ Functional studies
Durocher F et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet, 1996 comparing allele frequencies of E1038G between cancer cases and controls showed no statistically significant difference, consistent with benign status. Large-scale variant classification analyses⁴⁴ variant classification analyses
Easton DF et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet, 2007 applying multifactorial likelihood methods confirmed that E1038G retains near-normal BRCA1 function and is classified as benign or likely benign — it does not break the protein.

The question is whether this common polymorphism subtly modifies BRCA1 efficiency under conditions of DNA damage stress, enough to shift population-level cancer risk by a small margin without being individually pathogenic.

The Evidence

GWAS and association studies. Large-scale genome-wide association studies have mapped the 17q21 region containing BRCA1 as harboring common breast cancer susceptibility variants. A landmark GWAS⁵⁵ landmark GWAS
Easton DF et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007 established the framework for understanding how common variants in cancer-associated gene regions contribute to polygenic risk, with individual effect sizes typically in the OR 1.05-1.30 range — far below the 5-10x risk seen with pathogenic mutations.

A large-scale GWAS meta-analysis⁶⁶ large-scale GWAS meta-analysis
Michailidou K et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet, 2015 of more than 120,000 individuals identified 15 new breast cancer susceptibility loci, establishing that breast cancer risk has a significant polygenic component involving many common variants of small individual effect.

Risk modification context. The EMBRACE prospective analysis⁷⁷ EMBRACE prospective analysis
Mavaddat N et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst, 2013 followed BRCA1 and BRCA2 mutation carriers prospectively and estimated cumulative cancer risks, providing the quantitative risk context for understanding how common variants like E1038G differ from pathogenic BRCA1 mutations in their magnitude of effect. This underscores that common variants like E1038G are far removed from the penetrance of true BRCA1 mutations.

ClinVar consensus. The majority of ClinVar submissions classify E1038G as benign or likely benign (ClinVar variation ID 55398). The variant's high population frequency (~33% in Europeans) itself argues against pathogenicity — a truly harmful BRCA1 variant could not persist at this frequency. Some submitters note it as a variant of uncertain significance, reflecting the ambiguity of its small epidemiological signals.

Practical Implications

The key message: this variant does not warrant the clinical actions associated with pathogenic BRCA1 mutations. Prophylactic mastectomy, risk-reducing salpingo-oophorectomy, and intensive MRI surveillance protocols are for confirmed pathogenic BRCA1/2 carriers — not for carriers of this common polymorphism.

For women carrying one or two copies of the G allele, the evidence supports awareness rather than alarm. If you have additional breast cancer risk factors (family history, other genetic variants, dense breast tissue), this variant may be one small piece of a larger polygenic picture. In that context, discussing supplemental screening with your provider is reasonable.

For everyone, maintaining robust DNA repair capacity through adequate micronutrient intake is sensible. Folate, zinc, and selenium all play roles in DNA repair and genomic stability — though these are most relevant for carriers who want to optimize the DNA repair pathways this gene supports.

Interactions

The E1038G variant exists in a broader context of BRCA1 region variation. The related variant rs1799950 (BRCA1 E1038G's neighboring polymorphism) and rs11571833 (BRCA2 K3326X, a moderate-penetrance truncating variant) may combine with E1038G in polygenic risk models. Studies of polygenic risk scores for breast cancer incorporate many such common variants, and the combined effect of multiple small-effect alleles can meaningfully stratify risk across the population — even when each individual variant contributes only modestly.

The rare variant rs555607708 (BRCA1 pathogenic) represents the opposite end of the spectrum: a high-penetrance mutation that abolishes BRCA1 function. If a user carries both a common E1038G allele and a rare pathogenic BRCA1 variant on the other allele, the clinical management is driven entirely by the pathogenic mutation, not the common polymorphism.